Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
Breast Cancer
DRUG: INCB007839 300mg BID|DRUG: Trastuzumab|DRUG: Vinorelbine
Evaluation of safety and tolerabilty as determined by monitoring the frequency and severity of adverse events (AEs) and performing clinical assessments and laboratory investigations., Measured monthly starting at Baseline (estimated duration 6-9 months)
Overall objective response rate assessed by RECIST criteria, Measured at Baseline, Cycle 4 and approximately every 9 weeks after (estimated duration 6-9 months)
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.